MediPrint Ophthalmics reveals positive results from phase 2b study of LL-BMT1 contact lens

Author(s):

Key Takeaways

LL-BMT1, a weekly drug-eluting contact lens, effectively reduces intraocular pressure, matching bimatoprost 0.01% efficacy with fewer applications.
The lens significantly improves patient comfort and alleviates dry eye symptoms, with a 38% comfort improvement and 40% symptom relief.
MediPrint plans to initiate phase 3 trials and explore daily disposable lens market opportunities by 2025, focusing on comfort enhancement.

The weekly drug-eluting contact lens was created by the company’s proprietary 3D printing technology and met all primary endpoints with no serious adverse events reported in either cohort.

(Image Credit: AdobeStock/terovesalainen)

MediPrint Ophthalmics announced results from the company’s phase 2b clinical trial of LL-BMT1 at this year’s American Academy of Optometry meeting in Indianapolis.

LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens created by the company’s proprietary 3D printing technology, that delivers a sustained dose of bimatoprost and hyaluronic acid for the treatment of glaucoma. According to the company, the phase 2b clinical trial met all primary endpoints with no serious adverse events reported in either cohort.¹

In the study, the 32-µg dose of LL-BMT1 achieved equivalence to the efficacy of bimatoprost 0.01% in reduction of intraocular pressure (IOP). Furthermore, the company noted that patients with LL-BMT1 only required 6 lens insertions over the course of 3 weeks. This was an 86% reduction in treatment frequency compared to traditional daily eye drops.¹

The hyaluronic acid delivered by LL-BMT1 also allowed for a “significantly improved patient-reported comfort and relief from dry eye symptoms.” Patients in the chosen dose range, reported a 38% improvement in comfort as well as a 40% improvement in dry eye symptoms.¹

Ian Ben Gaddie, OD, FAAO, who presented the results at the AAOpt meeting stated, “LL-BMT1 represents a potential major step forward in glaucoma care, offering an effective, less burdensome alternative to daily eye drops and a less invasive option to laser or surgical modalities.”

The company stated that thanks to the results of the phase 2b study,¹ MediPrint plans to move forward with two programs in 2025. Programs will include focusing on comfort improvement, with hyaluronic acid in the daily disposable lens market as well as initiating the phase 3 clinical study of LL-BMT1 for glaucoma.

References:

MediPrint Ophthalmics Presents Promising Results from Phase 2b Clinical Trial of LL-BMT1 for Glaucoma at American Academy of Optometry. Press Release; November 12, 2024. Accessed November 12, 2024. https://www.businesswire.com/news/home/20241112595525/en/MediPrint-Ophthalmics-Presents-Promising-Results-from-Phase-2b-Clinical-Trial-of-LL-BMT1-for-Glaucoma-at-American-Academy-of-Optometry